This convergence of high unmet need, growing awareness and improving access to innovative therapies makes India a significant market for weight loss drugs. The drug company Novo Nordisk is also pushing for a share of the market
The FDA is requiring evaluations for long term, post-marketing safety of Saxenda in regards to cardiac effects, with post-marketing studies in children, and also to look for breast cancer and thyroid cancer incidents.
Zepbound is not FDA-approved for prediabetes or metabolic syndrome
Personalized GLP-1 Selection and Genetic Testing The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), and GIPR (rs1800437) variants that relate to GLP-1 and related signaling pathways
Many of these products can cause a spike in blood sugar, which then can counteract the beneficial effects of the GLP-1 medication
Dr Rossi is a consultant for Allergan Aesthetics, Almirall (Barcelona, Spain), Biofrontera (Leverkusen, Germany), Canfield Scientific (Parsippany, NJ), Cutera (Brisbane, CA), Dynamed (Ipswich, MA), Evolus, Evolve CME (Wayne, PA), Lam Therapeutics (Guilford, CT), Merz, Quantia MD (Waltham, MA), Regeneron (Tarrytown, NY), and Skinfix (Halifax, Nova Scotia, Canada)
